Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 1/20 | 0.45 |
| ▸ | RARA | P10276 | 4/20 | 0.44 |
| ▸ | RARG | P13631 | 4/20 | 0.44 |
| ▸ | RARB | P10826 | 2/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.41 |
| ▸ | ESR1 | P03372 | 4/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | MIF | P14174 | 1/20 | 0.35 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.35 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.35 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Idronoxil SCHEMBL149612 | 0.90 | ESR2 (0.49) | TYRRARARARGRARBESR2 | |
| Idronoxil SCHEMBL29353213 | 0.90 | ESR2 (0.49) | TYRRARARARGRARBESR2 | |
| SCHEMBL2742793 | 0.87 | RARA (0.44) | TYRRARARARGRARBMAPT | |
| SCHEMBL615450 | 0.84 | TYR (0.43) | TYRRARARARGRARBESR2 | |
| SCHEMBL616344 | 0.84 | RARA (0.46) | TYRRARARARGRARBESR2 | |
| SCHEMBL952469 | 0.84 | NR1H4 (0.54) | TYRRARARARGRARBESR2 | |
| SCHEMBL4549102 | 0.82 | TYR (0.55) | TYRRARARARGRARBESR2 | |
| SCHEMBL237510 | 0.79 | TYR (0.43) | TYRRARARARGRARBESR2 | |
| SCHEMBL26549421 | 0.79 | NISCH (0.48) | RARARARGRARBESR2ESR1 | |
| SCHEMBL616710 | 0.79 | RARA (0.49) | TYRRARARARGRARBNR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7915308-B2 | Therapeutic methods and compositions involving isoflavones | NOVOGEN RESEARCH PTY LTD (AU) | 2011-03-29 | — | — | US | disclosed |
| US-7906554-B2 | Combination chemotherapy compositions and methods | NOVOGEN RESEARCH PTY LTD (AU) | 2011-03-15 | — | — | US | disclosed |
| US-7875735-B2 | such as haginin E, equol, daidzein, formononetin; dealkylation, hydroboration, oxidation in presence of base, oxidation-dehydrogenation using 2,3-dichloro-5,6-dicyanobenzoquinone, and deprotecting | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2011-01-25 | — | — | US | disclosed |
| US-20100298581-A1 | Processes for Preparing Isoflavonoids using 7-benzyloxy-3-(4-methoxyphenyl)-2H-1-benzopyran as a Starting Material | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2010-11-25 | — | — | US | disclosed |
| US-20080261995-A1 | Pharmaceutical Combination of a Pde-5 Inhibitor and a 5-Alpha Reductase Inhibitor | PFIZER INC. | 2008-10-23 | — | — | US | disclosed |
| US-7202273-B2 | Therapeutic methods and compositions involving isoflavones | NOVOGEN RESEARCH PTY LTD (AU) | 2007-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298581-A1 | Processes for Preparing Isoflavonoids using 7-benzyloxy-3-(4-methoxyphenyl)-2H-1-benzopyran as a Starting Material | EGLN2, HABP2, CYP8B1 | TYR 1530/4885RARA 4445/4885RARG 3798/4885 |
| US-20080261995-A1 | Pharmaceutical Combination of a Pde-5 Inhibitor and a 5-Alpha Reductase Inhibitor | PDE5A, PDE12, QDPR | TYR 4779/4885RARA 3127/4885RARG 2793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.